Results 1 to 10 of about 29,513 (309)

Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]

BMC Infectious Diseases, 2019
Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Claudia Colomba, Laura Saporito, Paola Di Carlo, Manlio Tolomeo, Adriana Cervo, Alberto Firenze, Marcello Trizzino, Antonio Cascio   +7 more
doaj   +7 more sources

Current and Future Direct-Acting Antivirals Against COVID-19 [PDF]

Frontiers in Microbiology, 2020
The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed
Shiu-Wan Chan
doaj   +3 more sources

Virus infection and direct-acting antivirals in pregnancy

Clinical and Experimental Obstetrics & Gynecology, 2022
Objective: Antiviral therapy during pregnancy has always presented difficulties in clinical practice. This review covers the safety and efficacy of the direct use of antivirals during pregnancy.
Xuan Huang, Jing Tang
doaj   +1 more source

Treatment of Chronic HCV Infection with Direct Acting Antivirals

Central Asian Journal of Medical Sciences, 2021
Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren, Zulkhuu Genden, Odgerel Oidovsambuu, Anir Enkhbat, Ganbolor Jargalsaikhan, Sumiya Byambabaatar, Myammarsuren Shagdarsuren, Altankhuu Murdorj, Oyungerel Ravjir, Naranbaatar Dashdorj, Naranjargal Dashdorj, Dagvadorj Yagaanbuyant, Batbaatar Gunchin   +12 more
doaj   +1 more source

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C

Регуляторные исследования и экспертиза лекарственных средств, 2023
Scientific relevance. Direct-acting antivirals have significantly improved the effectiveness of treatment for hepatitis C. However, Russia and the Eurasian Economic Union lack recommendations for the clinical development of medicinal products from this ...
A. I. Gubenko, D. V. Goryachev, A. I. Muravieva, G. V. Shukshina   +3 more
doaj   +1 more source

Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection

The Egyptian Journal of Internal Medicine, 2022
Background Direct-acting antivirals (DAAs) have revolutionized the therapy of HCV infection with higher sustained virological response (SVR) rates. Fibrosis regression after achieving SVR to DAA remains to be evaluated in chronic hepatitis C patients ...
Ramy H. Agwa, Mohamed H. Elgazzar, Islam A. El-Zayyadi, Ahmed M. Saed, Mayada A. Ghannam, Ahmed Saleh   +5 more
doaj   +1 more source

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office

Acta Scientiarum. Health Sciences, 2023
To report the sociodemographic and clinical profile of patients treated with direct-action antivirals (DAAs). Patients infected with hepatitis C virus in current treatment were followed up in a pharmaceutical office.
Karem Aline Pegoraro, Edson Luiz Folador, Dennis Armando Bertolini, Angela Maria Campagna   +3 more
doaj   +1 more source

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study [PDF]

Clinical and Molecular Hepatology, 2017
Background/Aims Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons.
Kwang Il Seo, Byung Chul Yun, Weiquan James Li, Sang Uk Lee, Byung Hoon Han, Eun Taek Park   +5 more
doaj   +1 more source

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Viruses, 2021
The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe, Francesca Ceccherini-Silberstein, Julia Dietz, Stephanie Popping, Jason Grebely, Chaturaka Rodrigo, Johan Lennerstrand, Mark W. Douglas, Milosz Parczewsk, P. Richard Harrigan, Jean-Michel Pawlotsky, Federico Garcia, SHARED Collaborators   +12 more
doaj   +1 more source

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source